We describe an improvedenzymatic ultraviolet absorbance method for assaying creatinine in serum, plasma, and urine. Creatinine is hydrolyzed by creatinine iminohydrolase (EC 3.5.4.21) to ammonia and N-methylhydantoin. The ammonia produced combines with 2-oxoglutarateand NADPH in the presence of glutamate dehydrogenase to yield glutamate and NADP. The consumption of NADPH, measured by a two-point fixed-time assay, is proportional to the amount of creatinine in the sample. The assay is carried out in two steps: The first step eliminates background absorbance in hyperlipemic samples and endogenous ammonia through a "clearing system" and an isocitrate dehydrogenase-based "ammonia scavenger system"; the second step starts creatinine measurement. For more than 80 years, determinations of creatinine have relied on the reaction first described by Jaff#{233} (2). This method has been thoroughly described with regard to its merits-simplicity of assay, and low cost of re- Our goal was to develop an improved enzymatic method for assaying creatinine in serum, plasma, and urine that would retain the positive features of the enzymatic methods but overcome their drawbacks.
The kinetic measurement of color development dominates today in clinical laboratories. Nevertheless, many endogenous and exogenous compounds still influence the assay results, the effects depending on the formulation of the various alkaline picrate reagents and the specific assay conditions adopted.
In an attempt to measure "true" creatinine, various sequences of enzymatic reactions have been described (4). So far, only a few have been exploited in methods that have found application in the routine laboratory. One approach is based on the action of creatinine iminohydrolase (EC 3.5.4.21) and subsequent assay of the ammonia released by a NADPH-dependent reaction (7) or, in a multilayered dry-film technology, by measurement of the change in a pH indicator (8) . Another sequence uses creatinine ainidohydrolase (EC 3.5.2.10) and monitoring of the hydrogen peroxide produced via creatine aimdinohydrolase and sarcosine oxidase (9,10).
These enzymatic methods are not at present in widespread use because they still show several limitations. In ammonia detection methods, high concentrations of endogenous ammonia and glucose affect the measurement, as do lipemia and such drugs as 5-fluorocytosine and ranitidine. Moreover, the stability of the reagents is limited by the fast degradation of NADPH in the working solution. In hydrogen peroxide detection methods, have not been completely successful. Although accurate, the method based on adsorption of creatinine onto fuller's earth and the subsequent use of the Jaffe reaction is not suitable for routine work (11) . The same can be said for those methods based on different analytical techniques such as HPLC (12) and mass fragmentography (13-15).
Our goal was to develop an improved enzymatic method for assaying creatinine in serum, plasma 
Results
In this effort to set up a highly "robust" method to measure creatinine in human serum and urine, we considered as optimal those conditions that afforded firstorder reaction kinetics, greatest sensitivity with minimum lag phase,reduction of potential variables affecting manual and mechanized performances, and stable working solutions.
The reaction takes place at 37#{176}C in a buffered medium adjusted to pH 8.7, a compromise between that for the optimum catalytic activity of the enzymes (8.5-9.5 for creatinine iminohydrolase and 8.5 for glutamate dehydrogenase) and the stability of NADPH in solution.
The Michaelis constant for creatinine iminohydrolase (Km = 3.5 x iO molIL) is high enough to ensure that the enzyme-catalyzed reaction follows first-order kineticsin a wide range of creatinine concentrations. With an excessof added glutamate dehydrogenase, this reaction becomesthe rate-limiting step in the reaction sequence. Using 10 to 50 kUIL of creatinine iniinohydrolase yielded first-order kinetics for a range of creatinine concentrations up to 2210 moI/L in the interval from 30 to 300 s. The activity concentration that gave the highest assay sensitivity (absorbance change per 1 molJL creatinine) started at 27 kU/L and did not affect the sensitivity significantly up to 50 kUIL. This kinetics, combined with the exceptional stability of the enzyme in solution, avoids the frequent calibrations needed in the mechanized fixed-time procedures and provides for robust kinetic application.
The endogenous ammonia present in the sample at the beginning of the reaction leads to the consumption of 2-oxoglutarate and NADPH. Figure 1 shows typical reaction rates under assay conditions. To explore the reaction kinetics, we investigated the absorbance change due to the creatinine reaction in several human sera (normal and high in creatinine), human urine samples, and aqueous creatinine solutions. The reaction obeysfirst-order kinetics at least for 270 s after a 30-s lag phase. This behavior was indicated by straight sections of the curves generated by plotting vs time (x) the logarithm of the difference (y) between the absorbance at the end of the reaction and the absorbance every 15s.
Analytical Variables
Linearity. We assessedthe linearity of the method in both serum and saline. Stability. Different batehes of reagent solutions were tested for stability at 2-S #{176}C by assaying during a Crealinine difference between present (U), Jaff#{233} kInetic (0), and enzymatic colodmetrlc (A) methods and the fuller's earth method. bilirubin did not interfere with the present method even up to the highest bilirubin concentration tested (1050 imol/L). On the contrary, the Jaff#{233} kinetic and the enzymatic colorimetric methods showed significant negative interference (bias >20 moI/L creatinine) from bilirubin concentrations of 240 and 90 mol/L, respectively.
We also explored the effects on our method of adding potential interferents as well as of the more commonly used anticoagulants and urine preservatives. This "in vitro" study was performed according to the National Committee for Clinical Laboratory Standards guidelines (17). The various compounds were added at concentrations far exceeding their normal or therapeutic values to pooled human sera containing creatinine at -130 molfL.
These test pools were then each tested in five replicates. In parallel, control pools, prepared similarly but not supplemented with the potential interferent, were tested in 20 replicates.
When mean creatinine values for the test pools fell outside the calculated 2 SD ranges of control pools, we concluded that the added analyte caused interference.
We followed the same procedure to investigate the effect of urine preservatives, using in this case pooled human urines. No interference was found for any of the analytes at the concentrations presented in Table 4 .
In summary, no effect resulted from anticoagulantssuch as heparin, citrate, fluoride, oxalate, and even EDTA, expected toform a complex with magnesium-at concentrations at least double the common use for all compounds. Hyperbilirubinemia (bilirubin >40-fold the normal values), hemolysis (hemoglobin at least 25-fold the naked-eye-detected levels), and lipemia (turbidity 250-fold the absorption of a clear normal serum) did not show interference. No ammonia and creatine effect was evident for concentrations as great as 500-and 100-fold their normal serum levels.
Of the 72 drugs tested, none proved to be an interferent at itstherapeutic concentration in blood. In particular, several drugs known to interfere with the available creatinine enzymatic methods did not show an effect with the present creatinine assay, even at concentrations far exceeding their maximum therapeutic concentrations: calcium dobesilate (12-fold excess); cephalosporins of first, second, and third generation (even at 10-fold excess);and ranitidine (60-fold excess). The same was true for drugs with reducing effects such as ascorbic acid, methyldopa, and dopamine (>10-fold excess). No significant interference from 5-fluorocytosine at 78 mgfL was found; an overestimation of 22 moJ/L creatinine was evident only at about twice the therapeutic level (150 mgfL).
Last, we tested the effectiveness of the clearing system by monitoring the absorbance changes of the hyperlipemic samples. Twenty milky, fresh, hyperlipemic human sera containing triacylglycerol >5 mmol/L (range 5-23 mmol/L) were mixed with Solution 1. Subsequently the absorbance changes were monitored at 340 nm. Within 2 mm, the absorbance values for all the samples tested were similar to those of clear normal sera. For frozen-thawed hyperlipemic sera, a longer time (5-10 min) was needed for complete clarification.
Discussion
The method for measuring creatinine described here is suited for daily work in clinical laboratories yet is The innovative ammonia scavenger system has eliminated the drawbacks from possible high ammonia concentrations (e.g., in aged serum and urine samples) that lead to an excessive consumption of NADPH and 2-oxoglutarate and a reduced linearity range. This unique system not only prevents the interfering effect of preformed ammonia but also combines with the chosen pH of the solution to give exceptional stability to reagents. The system is capable of eliminating up to 5 mmol/L of endogenous ammonia and of ensuring a linear response up to at least 1768 tmolfL creatinine.
Urine specimens do not have to be pretreated to reduce ammonia concentration.
The inability to perform readings in light-distorting media, e.g., lipemic sera, has always been a frustrating problem, especially in ultraviolet measurement. The only possible exception was 5-fluorocytosine, which produced interference at borderline therapeutic concentrations.
In conclusion, the method we describe is highly specific, accurate, precise, and simple and rapid enough for easy automation; it also uses stable reagents. Such unique characteristics make this method particularly attractive for routine use in clinical laboratories.
